Review of the Safety and Efficacy of Linagliptin as Add-On Therapy to Metformin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study

References

• . Forst T, Uhlig-Laske B, Ring A,. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diabet Med. 2010;27(12):1409–1419
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Buse JB, Davidson MB,; American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2009;52(1):17–30
   PubMed Web of Science ®Google Scholar
• . Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazoli n-2-ylmethyl)-3,7-dihydro-purine 2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther. 2008;325(1):175–182
   PubMed Web of Science ®Google Scholar
• . Jellinger PS. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes. Postgrad Med. 2011;123(1):53–65
   PubMed Web of Science ®Google Scholar
• . Ahrén B, Foley JE, Ferrannini E,. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care. 2010;33(4):730–732
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Hissa MN, Garber AJ,; Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32(9):1649–1655
   PubMed Web of Science ®Google Scholar
• . Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med. 2010;27(3):318–326
   PubMed Web of Science ®Google Scholar
• . Göke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I; D1680C00001 Investigators. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract. 2010;64(12):1619–1631
   PubMed Web of Science ®Google Scholar
• . Matthews DR, Dejager S, Ahren B,. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010;12(9):780–789
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9(2):194–205
   PubMed Web of Science ®Google Scholar
• . Stirban AO, Tschoepe D. Cardiovascular complications in diabetes: targets and interventions. Diabetes Care. 2008;31( suppl 2):S215–S221
   Web of Science ®Google Scholar
• . Mari A, Scherbaum WA, Nilsson PM,. Characterization of the influence of vildagliptin on model-assessed-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab. 2008;93(1):103–109
   PubMed Web of Science ®Google Scholar
• . Yoon KH, Shockey GR, Teng R,. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes. Int J Clin Pract. 2011;65(2):154–164
   PubMed Web of Science ®Google Scholar
• . Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos. 2010;38(4):667–678
   PubMed Web of Science ®Google Scholar
• . Graefe-Mody U, Rose P, Ring A, Waldhauser L, Cinca R, Woerle HJ. The novel DPP-4 inhibitor linagliptin can be administered to patients with various degrees of hepatic impairment without dose adjustment. J Diabetes. 2011;3(s1):220
   Google Scholar
• . Merck & Co, Inc. Januvia® (sitagliptin) tablets prescribing information. Whitehouse Station, NJ: Merck & Co, Inc. January 2011. http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf. Accessed March 28, 2011
   Google Scholar
• . Novartis Pharmaceuticals UK Ltd. Galvus UK summary of product characteristics. Camberley, Surrey, UK: Novartis Pharmaceuticals UK Ltd. 28 February, 2011. http://www.medicines.org.uk/emc/medicine/20734/SPC/. Accessed March 28, 2011
   Google Scholar
• . Bristol-Myers Squibb Company. Onglyza (saxagliptin) tablets US prescribing information. Princeton, NJ: Bristol-Myers Squibb Company. February 2011. http://packageinserts.bms.com/pi/pi_onglyza.pdf. Accessed March 28, 2011
   Google Scholar
• . National Institute for Health and Clinical Excellence. Type 2 diabetes: The management of type 2 diabetes. NICE clinical guideline 87. London, UK: National Institute for Health and Clinical Excellence. May 2009. http://www.nice.org.uk/nicemedia/pdf/CG87NICEGuideline.pdf. Accessed March 28, 2011
   Google Scholar
• . Bhattacharyya OK, Shah BR, Booth GL. Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines. CMAJ. 2008;179(9):920–926
   PubMed Web of Science ®Google Scholar